Toronto, ON - December 22, 2025 - Astadaily, a Canadian wellness brand focused on vision health and microalgae-based nutrition, is contributing to the growing national conversation around digital eye strain as Canadians continue to report elevated daily screen exposure following the COVID-19 pandemic. The brand is supported by research conducted through its scientific partner, Iconthin Biotech Corp.
Prolonged screen time since the pandemic has made digital eye strain one of the most common vision-related complaints among working adults.
Digital eye strain, clinically referred to as Computer Vision Syndrome, has emerged as one of the most frequently reported concerns associated with prolonged digital device use. Canadian adults now spend an average of more than seven hours per day on screens, according to recent surveys, compared with approximately six hours before the pandemic. Optometry organizations in Canada report that nearly one in four individuals experience dry eye symptoms, a condition often linked to extended screen time and reduced blink rates.
Astadaily stated that its participation in this discussion reflects a broader effort to raise awareness of how nutrition science is being examined within the context of visual comfort and resilience. Peer-reviewed research has explored how specific nutrients, such as astaxanthin, lutein, and anthocyanins, may help the eyes respond to oxidative stress and blue-light exposure associated with sustained digital activity. These compounds have been studied individually and in combination for their potential roles in visual function and eye fatigue.
“As screen use has become an enduring part of work and daily life, conversations around vision health are increasingly relevant,” said Alvin Cheng scientist and founder of Astadaily, and CEO of Iconthin Biotech Corp. “From a research perspective, it is important to look at how nutrition science, sustainability, and public education intersect, particularly when discussing long-term visual comfort in a digital environment.”
Astadaily’s formulations are informed by research conducted at Iconthin Biotech Corp., where natural astaxanthin derived from microalgae is studied using supercritical CO₂ extraction—a clean, solvent-free method aligned with sustainability-focused development practices. Clinical research continues to investigate the role of nutrition in eye health. A randomized clinical trial published in the scientific literature (PMID: 36986186) evaluated an astaxanthin-based formulation combined with other eye-supporting nutrients and reported improvements in outcomes associated with visual strain. Astadaily emphasized that while such findings contribute to the expanding body of research, ongoing study and evidence-based discussion remain essential.
The timing of this announcement aligns with the holiday season, a period when many Canadians reflect on health habits and often experience increased screen use due to remote work, digital communication, and entertainment. Iconthin Biotech Corp. noted that its objective is to contribute factual, science-led perspectives to public dialogue without promoting specific treatments or outcomes.
Additional information on vision health, screen-time awareness, and microalgae-based nutrition is available at www.astadaily.com
About Astadaily
Astadaily is a Canadian wellness brand dedicated to advancing awareness of health and wellness through science-led education and microalgae-based nutrition. The brand focuses on evidence-informed formulations and public education around modern lifestyle challenges, including prolonged screen exposure.
About Iconthin Biotech Corp.
Iconthin Biotech Corp. is a Canadian biotechnology company specializing in research and development of microalgae-based nutritional ingredients, supporting innovation through sustainability-driven and evidence-based practices.
Media Contact
Company Name: Iconthin Biotech Corp.
Contact Person: Angela Ce
Email: Send Email
Phone: 1-888-730-6668
Country: Canada
Website: http://www.iconthin.com/
